Rapid Determination of Fingolimod Hydrochloride-Related Substances and Degradation Products in API and Pharmaceutical Dosage Forms by Use of a Stability-Indicating UPLC Method

被引:0
作者
N. Rajan
K. Anver Basha
机构
[1] Sathyabama University,Department of Chemistry
[2] C. Abdul Hakeem College,Department of Chemistry
来源
Chromatographia | 2014年 / 77卷
关键词
UPLC; Forced degradation; Fingolimod hydrochloride; Stability-indicating; Method validation;
D O I
暂无
中图分类号
学科分类号
摘要
Ultra-performance liquid chromatography coupled with photodiode-array detection has been used to develop a simple, sensitive, and reproducible reversed-phase method for quantitative determination of fingolimod hydrochloride and all possible process-related impurities. Chromatographic separation was achieved on a Waters Acquity BEH C18 (100 mm × 2.1 mm, 1.7 µm) column. The mobile phase was a gradient prepared from potassium dihydrogen phosphate (20 mM) containing 0.1 % (v/v) triethylamine and adjusted to pH 6.5 with trifluoroacetic acid (component A) and 85:15 (v/v) acetonitrile–water (component B); the gradient program (time (min)/% B) was: 0.01/20, 2.0/20, 6.0/75, 9.0/90, 12.0/90, 14.0/20, 16.0/20; the run time was 16 min and fingolimod hydrochloride and its six impurities were well separated. Eluting compounds were monitored at 220 nm. The method was validated for precision, specificity, linearity, limit of detection, limit of quantification, accuracy, and robustness in accordance with International Conference on Harmonization guidelines. Fingolimod hydrochloride was subjected to oxidative, acid, base, hydrolytic, thermal, and photolytic stress, and analysis was conducted to determine the amounts of related impurities formed.
引用
收藏
页码:1545 / 1552
页数:7
相关论文
共 20 条
  • [1] Portaccio E(2011)Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis Core Evid 6 13-21
  • [2] Aktas O(2010)Fingolimod is a potential novel therapy for multiple sclerosis Nat Rev Neurol 6 373-382
  • [3] Kury P(2011)New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate J Am Pharm Assoc 51 122-126
  • [4] Kieseier B(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
  • [5] Hartung H-P(2013)Study of aqueous phase aggregation of FTY720 (fingolimod hydrochloride) and its effect on DMPC liposomes using fluorescent molecular probes Phys Chem Chem Phys 15 17962-17970
  • [6] Hussar DA(2006)Synthesis of fingolimod Chin J New Drugs 15 802-804
  • [7] Zimmerman DE(2005)UPLC; an introduction and review J Liq Chromatogr RT 28 1253-1263
  • [8] Cohen JA(2006)Use of ultra-performance liquid chromatography in pharmaceutical development J Chromatogr A 140 1119-767
  • [9] Swain J(2001)Validation in pharmaceutical analysis, part 1: an integrated approach J Pharm Biomed Anal 24 755-870
  • [10] Mohapatra M(2005)Validation in pharmaceutical analysis, part II; Central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data J Pharm Biomed Anal 37 859-undefined